Trial
NCT01894022
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Phase IIITERMINATEDREGULATORYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Hypertension
Intervention
Ambrisentan 5 mg
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-11